Evidence map›Paper›PMID 33625242›Full record

SynthesisJournal of the American Heart Association2021

Effects of Sodium/Glucose Cotransporter 2 (SGLT2) Inhibitors on Cardiovascular and Metabolic Outcomes in Patients Without Diabetes Mellitus: A Systematic Review and Meta-Analysis of Randomized-Controlled Trials.

Yao Hao Teo, Yao Neng Teo, Nicholas L Syn, Cheryl Shumin Kow, Celine Shuen Yin Yoong, Benjamin Y Q Tan, Tiong-Cheng Yeo, Chi-Hang Lee, Weiqin Lin, Ching-Hui Sia

Open access · goldAbstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Journal of the American Heart Association, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 69 papers, 8 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
69citing papers in PubMed, 8 pooled it
14.4field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

69 citing papers in PubMed, 8 syntheses or guidelines pooled it, 135 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Trial
  10. Review
  11. Article
  12. Review
  13. Article
  14. Article
  15. Article
  16. Article
  17. Review
  18. Article
  19. Article
  20. Review

9 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yao Hao TeoDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Yao Neng TeoDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Nicholas L SynDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Cheryl Shumin KowDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Celine Shuen Yin YoongDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Benjamin Y Q TanDivision of Neurology University Medicine ClusterNational University Health System Singapore.
Tiong-Cheng YeoDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Chi-Hang LeeDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Weiqin LinDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
Ching-Hui SiaDepartment of Medicine Yong Loo Lin School of MedicineNational University of Singapore Singapore.
National University of Singapore · SGNational University Health System · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background Recent studies have increasingly shown that sodium-glucose cotransporter 2 (SGLT2) inhibitors may have beneficial cardiovascular and metabolic effects in patients without diabetes mellitus. Hence, we conducted a systematic review and meta-analysis to determine the effect of SGLT2 inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. Methods and Results Four electronic databases (PubMed, Embase, Cochrane, and SCOPUS) were searched on August 30, 2020 for articles published from January 1, 2000 to August 30, 2020, for studies that examined the effect of SGLT2 inhibitors on cardiovascular and metabolic outcomes in patients without diabetes mellitus. A random-effects pairwise meta-analysis model was used to summarize the studies. A total of 8 randomized-controlled trials were included with a combined cohort of 5233 patients. In patients without diabetes mellitus, those with heart failure treated with SGLT2 inhibitors had a 20% relative risk reduction in cardiovascular deaths and heart failure hospitalizations, compared with those who were not treated (risk ratio, 0.78;

Indexed as

Randomized Controlled Trials as TopicBlood GlucoseCardiovascular DiseasesDiabetes Mellitus, Type 2HumansSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 InhibitorsBlood GlucoseSodium-Glucose Transporter 2Sodium-Glucose Transporter 2 Inhibitorsnondiabeticssodium/glucose cotransporter 2 inhibitors

Identifiers

PMID33625242
PMCPMC8174267
OpenAlexW3133465269

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.